In the BioHarmony Drug Report Database

"Preview" Icon

Trabectedin

Yondelis (trabectedin) is a small molecule pharmaceutical. Trabectedin was first approved as Yondelis on 2007-09-17. It is used to treat leiomyosarcoma and liposarcoma in the USA. It has been approved in Europe to treat ovarian neoplasms and sarcoma. It is known to target nuclear receptor subfamily 1 group I member 2. Yondelis’s patent is valid until 2028-01-07 (FDA).

 

Trade Name

 

Yondelis
 

Common Name

 

trabectedin
 

ChEMBL ID

 

CHEMBL450449
 

Indication

 

leiomyosarcoma, liposarcoma, ovarian neoplasms, sarcoma
 

Drug Class

 

Ecteinascodin derivatives

Image (chem structure or protein)

Trabectedin structure rendering